Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients : vimarsana.com

Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients

Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Jenny Kobin Remy Bernarda , Thomasa Ciulla , Development Officer , Exchange Commission , Nasdaq , Clearside Biomedical Inc , Wall Street , Chief Medical Officer , Chief Development , Clinical Trial , Neovascular Age Related Macular Degeneration , Suprachoroidal Space , Injection Platform , Private Securities Litigation Reform Act , Annual Report , Periodic Reports , Media Contacts , Clearside Biomedical ,